With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears ...

Eli Lilly and Company is unveiling its new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, which will be available ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under ...